The 6 most recent market catalysts affecting $CALC, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 27, 2026
Corporate Catalyst
Bearish
Impact 85
CalciMedica shares are trading lower after the company announced a 1-for-5 reverse stock split.
A reverse stock split is often viewed negatively by the market as it can indicate a company is struggling to maintain its share price above minimum exchange requirements or is faci…
Aug 27, 2026
Corporate Catalyst
Neutral
Impact 65
CalciMedica Announces 1-For-5 Reverse Stock Split, Effective August 28
CalciMedica announced a 1-for-5 reverse stock split, effective August 28, 2026, with trading on a split-adjusted basis commencing August 31, 2026. This action was approved by stock…
Aug 20, 2026
Corporate Catalyst
Neutral
Impact 65
Guggenheim Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $9
Guggenheim analyst Vamil Divan initiated coverage on CalciMedica (CALC) with a 'Buy' rating and a $9 price target. This event is significant for CalciMedica as new analyst coverage…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 90
CalciMedica Q2 EPS $(0.45) Misses $(0.28) Estimate
CalciMedica (CALC) announced Q2 earnings per share of $(0.45), which was a substantial miss compared to the analyst consensus estimate of $(0.28). This 60.71% deviation from expect…
Jul 29, 2026
Corporate Catalyst
Neutral
Impact 75
Following Type C FDA Meeting, Calcimedica Has Aligned On Phase 2b Trial Endpoints And Patient Population Enrichment Strategy For Its Planned Registration Program Evaluating Auxora In Acute Pancreatitis
CalciMedica has secured crucial alignment with the FDA regarding the design of its Phase 2b trial for Auxora in acute pancreatitis. This includes agreement on new-onset severe resp…
Jul 24, 2026
Corporate Catalyst
Neutral
Impact 65
CalciMedica Files Prospectus For Resale Of Up To 56,020,287 Shares
CalciMedica filed a prospectus to register up to 56,020,287 shares for resale by existing selling stockholders. This is not a primary offering by the company to raise capital, but …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.